Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Delta-9-THC Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Pharmacology of THC and Alpha-pinene

NCT04130633
View directory record Official record
Conditions
THC, Alpha-pinene
Interventions
Placebo, THC, Alpha-Pinene
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 7, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

NCT04360044
View directory record Official record
Conditions
Migraine, Cannabis, THC, CBD
Interventions
THC ~5%, CBD ~12%, THC ~5% and CBD ~12%, Sham Cannabis
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 7, 2026, 10:37 PM EDT
Not yet recruiting Phase 3 Interventional

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

NCT07148206
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

NCT06222268
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
Interventions
Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only, THC:CBD 1:1
Drug
Lead sponsor
Leslie Lundahl
Other
Eligibility
18 Years to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Withdrawn Phase 2 Interventional

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

NCT06834997
View directory record Official record
Conditions
Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions
Dronabinol Capsules, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hosuton, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Behavioral Pharmacology of Orally Administered THC and D-limonene

NCT06378957
View directory record Official record
Conditions
Subjective Drug Effects, THC, D-limonene
Interventions
D-Limonene, Delta-9-THC, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT04984278
View directory record Official record
Conditions
Spasticity With Multiple Sclerosis
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 7, 2026, 10:37 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Behavioral and Physiological Effects of THC and CBD

NCT03832816
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Vaporized THC alone, Vaporized CBD alone, Vaporized CBD with THC
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Sep 7, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

NCT01262651
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
GW Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • El Cajon, California • Gilroy, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 7, 2026, 10:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

NCT06859710
View directory record Official record
Conditions
Abuse, Drug, Pain
Interventions
Placebo, THC, CBD 20 mg, CBD 40 mg, CBD 80 mg
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 7, 2026, 10:37 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

NCT04203498
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 7, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.

NCT00530764
View directory record Official record
Conditions
Palliative Care, Pain, Cancer
Interventions
Sativex Low Dose, Sativex Medium Dose, Sativex High Dose
Drug
Lead sponsor
GW Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Casa Grande, Arizona • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 7, 2026, 10:37 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I

NCT02709954
View directory record Official record
Conditions
Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions
Active inhaled delta-9-THC, Placebo, Active Oral Ethanol
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

NCT05906511
View directory record Official record
Conditions
Pain, Tolerance, Oral vs Vaporized THC, Abuse Liability
Interventions
Dronabinol 5 MG, Dronabinol 10 MG, 2mg Purified THC in an ethanolic solution, 4mg Purified THC in an ethanolic solution, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Combined THC and CBD for OUD and Chronic Pain

NCT06544291
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder
Interventions
CBD 300mg, CBD 600mg, Placebo 0mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

NCT02102113
View directory record Official record
Conditions
Psychosis, Cannabis Use, THC, Marijuana, Schizophrenia
Interventions
Placebo, Very Low Dose THC, Low Dose THC
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 7, 2026, 10:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoid Modulation of Pain

NCT01595620
View directory record Official record
Conditions
Pain
Interventions
Thermal, Electrical, Capsaicin, THC, Placebo
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 7, 2026, 10:37 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)

NCT04859296
View directory record Official record
Conditions
Pain, Appetite Loss, Abuse, Drug
Interventions
Placebo, Low CBG, High CBG, Low THC, High THC
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

NCT02576912
View directory record Official record
Conditions
Healthy
Interventions
Active Delta-9-THC, Active Pregnenolone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 7, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

NCT02811939
View directory record Official record
Conditions
Healthy
Interventions
Active Dronabinol, Active Pregnenolone, Placebo Dronabinol, Placebo Pregnenolone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 7, 2026, 10:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

NCT06058702
View directory record Official record
Conditions
Schizophrenia, Cannabis Use Disorder
Interventions
Delta-9-THC Very Low Dose, Placebo, Delta-9-THC Medium Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 10:37 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

N-acetylcysteine Effects on Tetrahydrocannabinol

NCT02335060
View directory record Official record
Conditions
Healthy
Interventions
Delta-9-THC, N-acetylcysteine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 7, 2026, 10:37 PM EDT
Completed Phase 4 Interventional Results available

Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study

NCT03008005
View directory record Official record
Conditions
PostTraumatic Stress Disorder
Interventions
Placebo Oral Capsule, Dronabinol Cap 5 milligrams (MG), Dronabinol Cap 10 milligrams (MG)
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 7, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain

NCT02460692
View directory record Official record
Conditions
Cannabis, Low Back Pain, Neuropathic Pain
Interventions
Placebos, dronabinol, Vaporized Cannabis 3.7% THC/5.6% CBD
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
19 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 7, 2026, 10:37 PM EDT